Director/PDMR Shareholding

    RNS Number : 0088I
  Inion Oy
  12 November 2008
   

    


    Inion Oy 
    ("Inion or "the Company")

    Payment of Non-Executive Directors' Fees in Shares

    Tampere, Finland and Guildford, UK. 12 November 2008*Inion [LSE: IIN.L], a company focused on the development of novel biodegradable
medical implants, announces that its Non-Executive Directors have received Inion shares in lieu of 50% of their directors' fees in respect
of the quarter ended 30 September 2008. This is part of a share-based payment scheme previously announced on 8 October 2007.

    The share price used to calculate the number of shares issued to each Director was 8.75p, representing the closing mid-market share
price on 30 September 2008, the last working day of the third quarter of 2008.


 Non-Executive Director    No. of ordinary     Share price (p)   Total shareholding   % of current issued
                         shares of  EUR 0.03                      following issue        share capital
                                issued
 Ian Paling                     38,043              8.75p             40,1281                 0.05
 David Anderson                 42,857              8.75p             126,578                 0.17
 Jim Beery                      46,429              8.75p             137,127                 0.18
 Peter Jensen                   50,000              8.75p             147,674                 0.19
 Markku Sil                     46,429              8.75p             137,127                 0.18

    1This includes 2,085 shares which are held by Mr Paling as Trustee for the beneficial ownership of connected persons.
    -Ends-

    For further information, please contact:
 Inion Oy                                        Tel: [phone]
 Chris Lee, Chief Executive Officer
 Julien Cotta, Chief Financial Officer

 Citigate Dewe Rogerson                          Tel: [phone]
 Mark Swallow / Helena Galilee / David Dible

    About Inion (www.inion.com)
    Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments. 

    Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation
     
Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate
patient rehabilitation.

    Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland.

    This announcement includes "forward-looking statements" which include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results,
performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to
rely on any forward-looking statement.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDSILFIFLALFLIT